NovoCure Ltd. Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. NovoCure Ltd. is a global oncology company developing and commercializing Tumor Treating Fields (TTFields) devices, including Optune Gio (glioblastoma), Optune Lua (NSCLC and mesothelioma), and Optune Pax (pancreatic cancer). The company operates in a single reportable segment with significant revenue contributions from the U.S., Germany, France, and Japan.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenues | $174.1 million | $155.0 million |
| Gross Profit | $135.1 million | $116.5 million |
| Gross Margin | 78% | 75% |
| Operating Loss | $(67.4) million | $(37.9) million |
| Net Loss | $(71.1) million | $(34.3) million |
| Net Loss Per Share | $(0.62) | $(0.31) |
| Cash & Short-Term Investments | $432.0 million | $447.7 million (Dec 2025) |
| Long-Term Debt (Principal) | $200.0 million | $200.0 million |
| Operating Cash Flow | $(13.5) million | $(35.7) million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 12% year-over-year, driven by $16.3 million in international growth (Germany, France, Spain) and $2.8 million in U.S. growth. Active patient count rose to 4,791 (up from 4,268 in Q1 2025).
- Expense Surge: General and Administrative (G&A) expenses jumped 92% to $85.9 million. This was primarily due to a one-time, non-cash expense of approximately $43.4 million related to the vesting of Performance Share Units (PSUs) triggered by the FDA approval of Optune Pax.
- Financial Income: Net financial income turned to an expense of $1.8 million (from $7.6 million income in Q1 2025) due to lower interest income from maturing convertible notes and higher interest expenses on the senior secured credit facility.
- Debt Status: The company has drawn $200 million of its $400 million credit facility (Tranches A and B). The option to draw Tranches C and D expired without notice, meaning no further borrowing is available under this facility.
Guidance, Outlook, and Risks
- Regulatory Milestones: Optune Pax received FDA approval for pancreatic cancer in February 2026. The company submitted a PMA application for Optune Mya (brain metastases from NSCLC) in December 2025 following positive Phase 3 METIS trial results.
- Clinical Pipeline: The Phase 2 PANOVA-4 trial for metastatic pancreatic cancer met its primary endpoint. The company is exploring design modifications for the LUNAR-2 trial to reduce costs and timeline.
- Liquidity: Management believes current cash and short-term investments ($432 million) are sufficient for operations for at least the next 12 months. However, operating expenses are expected to outpace gross profit as the company expands into new indications, potentially requiring additional capital raises.
- Risks: Key risks include supply chain disruptions due to conflict in Israel (mitigated by increased inventory and second-sourcing), potential impacts from U.S. tariff changes, and the ability to secure reimbursement coverage for new indications.
Investor Verification Checklist
- Non-Cash Expense Impact: Verify the $43.4 million G&A charge related to PSU vesting is excluded from future quarters to assess true operating cost trends.
- Debt Capacity: Confirm the inability to access the remaining $200 million of the credit facility and evaluate the timeline for potential new financing needs.
- Reimbursement Rates: Monitor the sustainability of the $3.5 million in one-time revenue benefits from Germany and France cited in the quarter.
- Supply Chain Resilience: Assess progress on onboarding second-source suppliers outside of Israel and the status of new production capacity in Mexico and Ireland.
- Optune Pax Adoption: Track the conversion of the 169 new Optune Pax prescriptions received in Q1 into recurring revenue.